-
1.发明申请COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) AN ANTIDIABETIC COMPOUND FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES 审中-公开（A）磷酸三磷酸激酶抑制剂的组合和（B）用于治疗增殖性疾病的抗生素化合物公开(公告)号：US20120059005A1
公开(公告)日：2012-03-08
申请号：US13319536
申请日：2010-05-12
申请人： Jose Baselga , Serena Di Cosimo , Carlos Garcia-Echeverria , Wolfgang Hackl , Sauveur-Michel Maira , Russillo Michelangelo , Violeta Serra Elizalde
发明人： Jose Baselga , Serena Di Cosimo , Carlos Garcia-Echeverria , Wolfgang Hackl , Sauveur-Michel Maira , Russillo Michelangelo , Violeta Serra Elizalde
IPC分类号： A61K31/5377 , A61K31/437 , A61P35/00
CPC分类号： A61K45/06 , A61K31/155 , A61K31/426 , A61K31/427 , A61K31/437 , A61K31/4439 , A61K31/496 , A61K31/5377 , A61K2300/00
摘要： The invention relates to a pharmaceutical combination which comprises (a) a phosphoinositide 3-kinase inhibitor compound and (b) an insulin sensitivity enhancer compound for the treatment of a proliferative disease, especially a solid tumor disease; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of a proliferative disease; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a warm-blooded animal, especially a human.
摘要翻译： 本发明涉及一种药物组合，其包含（a）磷酸肌醇3-激酶抑制剂化合物和（b）用于治疗增殖性疾病，特别是实体瘤疾病的胰岛素敏感性增强剂化合物; 包含这种组合的药物组合物; 使用这种组合来制备用于治疗增殖性疾病的药物; 包括作为用于同时，分开或顺序使用的组合制剂的组合的商业包装或产品; 以及治疗温血动物，特别是人的方法。
-
公开(公告)号：US20050019785A1
公开(公告)日：2005-01-27
申请号：US10714195
申请日：2003-11-14
申请人： Joffre Baker , Maureen Cronin , Steve Shak , Jose Baselga
发明人： Joffre Baker , Maureen Cronin , Steve Shak , Jose Baselga
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
公开(公告)号：US08008003B2
公开(公告)日：2011-08-30
申请号：US10714195
申请日：2003-11-14
申请人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
发明人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
公开(公告)号：US20120178644A1
公开(公告)日：2012-07-12
申请号：US13347555
申请日：2012-01-10
申请人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
发明人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
公开(公告)号：US08148076B2
公开(公告)日：2012-04-03
申请号：US13150799
申请日：2011-06-01
申请人： Joffre B. Baker , Maureen T. Cronin , Steven Shak , Jose Baselga
发明人： Joffre B. Baker , Maureen T. Cronin , Steven Shak , Jose Baselga
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
公开(公告)号：US20110245102A1
公开(公告)日：2011-10-06
申请号：US13150799
申请日：2011-06-01
申请人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
发明人： Joffre B. Baker , Maureen T. Cronin , Steve Shak , Jose Baselga
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/16
摘要： The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
摘要翻译： 本发明涉及与EGFR阳性癌症相关的预后标志物。 特别地，本发明涉及基于在石蜡包埋的EGFR表达癌症的固定组织样品中的基因表达的分子表征的预后方法，其允许医师预测患者是否可能对EGFR抑制剂的治疗反应良好 。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.037 秒)
